Lilly: U.S. Buying Additional Doses of Neutralizing Antibody Therapy for Covid-19

By Michael Dabaie

Eli Lilly & Co. said the U.S. government agreed to purchase a minimum of 100,000 doses of bamlanivimab 700 mg and etesevimab 1400 mg together.

The purchase agreement is for $210 million and doses will be delivered through March 31. The U.S. government will have the option to purchase up to an additional 1.1 million doses through Nov. 25, under the same terms, subject to agreement from Lilly, product availability and the medical need in the U.S.

This purchase adds to the supply of neutralizing antibodies already available for use in the U.S. The government has already committed to purchase a total of 1.45 million doses of bamlanivimab alone, which includes more than one million doses that have been delivered and an agreement to deliver 450,000 additional doses by March 31.

Bamlanivimab and etesevimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate Covid-19 in patients who are at high risk of progressing to severe Covid-19 and hospitalization.

Lilly said the National Institutes of Health recently updated the Covid-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate Covid-19 who are at high risk of clinical progression.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

February 26, 2021 07:59 ET (12:59 GMT)

Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024